Timur Dogan
Directeur Technique/Scientifique/R&D chez CARDIO DIAGNOSTICS HOLDINGS, INC.
Fortune : 92 665 $ au 30/04/2024
Profil
Timur Dogan is currently the Chief Technology Officer at Cardio Diagnostics Holdings, Inc. He previously held the same position at Cardio Diagnostics, Inc. Dr. Dogan obtained his undergraduate, graduate, and doctorate degrees from the University of Iowa.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
01/04/2024 | 128 345 ( 0,59% ) | 92 665 $ | 30/04/2024 |
Postes actifs de Timur Dogan
Sociétés | Poste | Début |
---|---|---|
CARDIO DIAGNOSTICS HOLDINGS, INC. | Directeur Technique/Scientifique/R&D | 25/10/2022 |
Anciens postes connus de Timur Dogan
Sociétés | Poste | Fin |
---|---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The private company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Directeur Technique/Scientifique/R&D | - |
Formation de Timur Dogan
University of Iowa | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
CARDIO DIAGNOSTICS HOLDINGS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The private company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Health Services |